Accessibility Menu
Arrow-Thin-Down
S&P 500
6,890.59
-0.0%
-0.30
Arrow-Thin-Down
DJI
47,632.00
-0.2%
-74.37
Arrow-Thin-Down
NASDAQ
23,958.47
+0.5%
+130.98
Arrow-Thin-Down
Bitcoin
$110,550.00
-2.0%
-$2,280.80
Arrow-Thin-Down
AAPL
$269.22
+0.1%
+$0.22
Arrow-Thin-Down
AMZN
$230.12
+0.4%
+$0.87
Arrow-Thin-Down
GOOG
$275.45
+2.6%
+$7.02
Arrow-Thin-Down
META
$751.67
+0.0%
+$0.23
Arrow-Thin-Down
MSFT
$541.55
-0.1%
-$0.52
Arrow-Thin-Down
NVDA
$207.00
+3.0%
+$5.97
Arrow-Thin-Down
TSLA
$461.54
+0.2%
+$0.99
Daily Stock GainersDaily Stock LosersMost Active Stocks
Creative Medical Technology Stock Quote

Creative Medical Technology (NASDAQ: CELZ)

$3.76
(-32.7%)
-1.83
Price as of October 29, 2025, 4:00 p.m. ET

KEY DATA POINTS

Current Price
$3.76
Daily Change
(-32.7%) $1.83
Day's Range
$3.53 - $5.48
Previous Close
$3.76
Open
$5.34
Beta
0.76
Volume
604,693
Average Volume
90,283
Sector
Health Care
Market Cap
14.4M
Market Cap / Employee
$5.59M
52wk Range
$1.69 - $6.90
Revenue
-
Gross Margin
-18.27%
Dividend Yield
N/A
EPS
-$3.17
CAPs Rating
-
Industry
Biotechnology

The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More

Creative Medical Technology Return vs. S&P

1 Year5 Year5 Year AnnualizedSince IPO
CELZ+41.88%N/AN/A-100%
S&P+18.33%+108.18%+15.79%+238%

Creative Medical Technology Company Info

Creative Medical Technology Holdings, Inc. is a commercial stage biotechnology company which focuses on immunology, urology, neurology and orthopedics using adult stem cell treatments and interrelated regenerative technologies for the treatment of multiple indications. Its products include CaverStem, FemCelz, StemSpine, and ImmCelz. The company was founded on December 3, 1998 and is headquartered in Phoenix, AZ.

Financial Health

General

Q2 2025YOY Change
Revenue$0.00M-100.0%
Gross Profit-$0.03M-25.6%
Gross Margin-959.23%0.0%
Market Cap$6.85M32.0%
Market Cap / Employee$1.71M0.0%
Employees40.0%
Net Income-$1.23M20.8%
EBITDA-$1.23M22.8%

Currently no data to display

Revenue Growth Rate

Currently no data to display.

Earnings Per Share Growth Rate

Currently no data to display.

Assets

Q2 2025YOY Change
Net Cash$6.54M-12.4%
Inventory0-70.7%

Liabilities

Q2 2025YOY Change
Long Term Debt$0.00M0.0%
Short Term Debt$0.00M0.0%

Ratios

Q2 2025YOY Change
Return On Assets-76.39%-24.6%
Return On Invested Capital15.52%-38.3%

Cash Flow

Q2 2025YOY Change
Free Cash Flow-$1.16M21.1%
Operating Free Cash Flow-$1.16M21.1%

Valuation

MetricQ3 2024Q4 2024Q1 2025Q2 2025YoY Change
Price to Book0.540.470.600.8550.12%
Price to Sales392.36346.79307.011139.73258.14%
Price to Tangible Book Value0.570.510.650.9052.90%
Enterprise Value to EBITDA1.801.142.09-0.24-118.48%
Return on Equity-57.0%-65.8%-70.4%-79.9%48.66%
Total Debt$0.00M$0.00M$0.00M$0.00M-

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services